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ABSTRACT 
Cannabis sativa preparations are the most commonly used illicit drugs worldwide. The pre-
sent study aimed to investigate the effect of Cannabis sativa extract in the working memory 
version of the Morris water maze (MWM; Morris, 1984) test and determine the effect of 
standard memory enhancing drugs. Cannabis sativa was given at doses of 5, 10 or 20 mg/kg 
(expressed as 9-tetrahydrocannabinol) alone or co-administered with donepezil (1 mg/kg), 
piracetam (150 mg/ kg), vinpocetine (1.5 mg/kg) or ginkgo biloba (25 mg/kg) once daily sub-
cutaneously (s.c.) for one month. Mice were examined three times weekly for their ability to 
locate a submerged platform. Mice were euthanized 30 days after starting cannabis injection 
when biochemical assays were carried out. Malondialdehyde (MDA), reduced glutathione 
(GSH), nitric oxide, glucose and brain monoamines were determined. Cannabis resulted in a 
significant increase in the time taken to locate the platform and enhanced the memory im-
pairment produced by scopolamine. This effect of cannabis decreased by memory enhancing 
drugs with piracetam resulting in the most-shorter latency compared with the cannabis. Bio-
chemically, cannabis altered the oxidative status of the brain with decreased MDA, increased 
GSH, but decreased nitric oxide and glucose. In cannabis-treated rats, the level of GSH in 
brain was increased after vinpocetine and donepezil and was markedly elevated after Ginkgo 
biloba. Piracetam restored the decrease in glucose and nitric oxide by cannabis. Cannabis 
caused dose-dependent increases of brain serotonin, noradrenaline and dopamine. After can-
nabis treatment, noradrenaline is restored to its normal value by donepezil, vinpocetine or 
Ginkgo biloba, but increased by piracetam. The level of dopamine was significantly reduced 
by piracetam, vinpocetine or Ginkgo biloba. These data indicate that cannabis administration 
is associated with impaired memory performance which is likely to involve decreased brain 
glucose availability as well as alterations in brain monoamine neurotransmitter levels. Pirace-
tam is more effective in ameliorating the cognitive impairments than other nootropics by alle-
viating the alterations in glucose, nitric oxide and dopamine in brain.  
 
Keywords: Cannabis sativa extract, nootropics, water maze, mice, oxidative stress, brain 
monoamines 
 
 
INTRODUCTION 
The cannabis preparations marijuana 
and hashish are the most popular and most 
commonly used illicit drugs worldwide. 
These are derived from the female plant of 
Cannabis sativa L (family Cannabinaceae). 
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Marijuana is prepared from the dried flow-
ering tops and leaves; hashish consists of 
dried cannabis resin and compressed flow-
ers (Ashton, 2001). Cannabinoids are a 
group of C21 terpenophenolic compounds 
uniquely produced by Cannabis sativa 
plant. The primary psychoactive constituent 
is 9-tetrahydrocannabinol (THC) (Mech-
oulam and Gaoni, 1967). Other plant can-
nabinoids include 8-THC, cannabinol and 
cannabidiol (Adams and Martin, 1996).  
Memory or the retention of learned in-
formation is fundamental to human beings. 
Cannabis use causes working and short-
term memory deficits in humans as well as 
in experimental animals (Solowij and Bat-
tisti, 2008; Fadda et al., 2004). This effect 
applies to both short and long-term use of 
cannabis (Solowij and Battisti, 2008; 
Solowij et al., 2011); the impairments may 
persist well beyond the period of intoxica-
tion, and recovery of functions might take 
weeks following abstinence (Pope et al., 
2001) or persist for longer time (Solowij et 
al., 2002). In chronic users, cannabis might 
impair the ability to learn and remember 
new information. Early onset, long-term use 
and higher frequency of use are seen as risk 
factors for cognitive impairments (Harvey 
et al., 2007). Cannabinoids exert their ef-
fects by interaction with specific endoge-
nous cannabinoid receptors. Two G protein-
coupled cannabinoid receptor subtypes 
have been cloned: CB1 receptor which is 
widely distributed throughout the brain, but 
particularly in the cerebral cortex, hippo-
campus, cerebellum, thalamus and basal 
ganglia (the brain regions involved in cog-
nition, memory, reward, pain perception, 
and motor coordination) and CB2 receptor 
which is mainly expressed on immune cells, 
but also in central nervous system. These 
receptors also respond to endogenous lig-
ands, the endocannabinoids such as anan-
damide and 2-arachidonoylglycerol, which 
are arachidonic acid derivatives. Canna-
binoid CB1 receptors were identified in the 
hippocampus, the brain region most closely 
associated with memory (Pertwee and Ross, 
2002; Pertwee, 2005; Svíženská et al., 
2008). The precise nature of memory defi-
cits in cannabis users and their neural sub-
strates still require further research (Solowij 
and Battisti, 2008).  
In the treatment of memory disorders 
whether occurring as a part of normal aging 
or due to a pathological process e.g., Alz-
heimer's disease, drugs such as piracetam, 
vinpocetine, Ginkgo biloba or donepezil 
which improve learning and memory are 
frequently prescribed (McDaniel et al., 
2003). Piracetam was the first of the so 
called "nootropics", a term introduced by 
Giurgea (1973) to indicate this category of 
drugs that enhance memory, facilitate learn-
ing and protect memory processes against 
conditions which tend to disrupt them. The 
drug is a pyrrilodine derivative (2-oxo-1-
pyrrolidine acetamide), a cyclic derivative 
of gamma-aminobutyric acid, which has 
been shown to facilitate learning and pre-
serve memory from disruption under differ-
ent experimental conditions (Gouliaev and 
Senning, 1994; He et al., 2008). Piracetam 
enhances recovery from post-stroke aphasia 
(Kessler et al., 2000), improves cognitive 
performance in the elderly (Waegemans et 
al., 2002) and in patients undergoing bypass 
surgery (Holinski et al., 2008). The drug 
possesses rheological, blood flow promot-
ing effects (Müller et al., 1999) and mito-
chondrial membrane stabilizing properties 
(Keil et al., 2006; Leuner et al., 2010). 
Vinpocetine (vinpocetine-ethyl apovin-
caminate), a synthetic derivative of the al-
kaloid vincamine from periwinkle (Vinca 
minor) is phosphodiesterase (PDE) inhibi-
tor, selective for PDE1 (van Staveren et al., 
2001) and a blocker of voltage-gated Na+ 
channels (Sitges et al., 2006) which im-
proves learning and memory deficits in ro-
dents (DeNoble, 1987). The drug is widely 
used to improve the cognitive functions of 
patients with cerebrovascular disease and 
chronic cerebral hypoperfusion (Horváth, 
2001) and to decrease the risk of transient 
ischemic attacks and strokes in patients 
with chronic cerebrovascular insufficiency 
(Valikovics, 2007). Vinpocetine is a potent 
vasodilator at the cerebral vascular bed, in-
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creasing cerebral blood flow and regional 
cerebral glucose uptake (Vas et al., 2002).  
Standardized extracts from the leaves of 
Ginkgo biloba contains 24 % ginkgo-flavo-
ne glycosides and 6 % terpenoids (gink-
golides, bilobalide). Ginkgo biloba extracts 
are widely used to improve cognition and 
memory in cerebral insufficiency and mild 
cognitive impairment (Bäurle et al., 2009). 
The extract also showed a beneficial effect 
in reducing the total and negative symp-
toms of chronic schizophrenia when used as 
an add-on therapy to antipsychotic medica-
tion (Singh et al., 2010). Ginkgo biloba 
prevented stress- and corticosterone-
induced impairments of spatial memory and 
reduced neuronal loss in hippocampus (Ta-
kuma et al., 2007; Walesiuk and Braszko, 
2009). Ginkgo biloba also showed neuro-
protective and therapeutic effects in exper-
imental cerebral ischemia (Saleem et al., 
2008) and attenuated the toxin-induced neu-
rodegeneration of the nigrastriatal pathway 
(Rojas et al., 2008). The extract has been 
shown to possess vasodilator and blood 
flow enhancing (Chung et al., 1999) as well 
as antioxidant and free radical scavenging 
properties (Rojas et al., 2008).  
The main neurochemical deficit seen in 
Alzheimer's disease is reduced acetylcho-
line content and choline acetyltransferase 
activity (the enzyme synthesizing acetyl-
choline) in the nucleus basalis of Meynert 
and the hippocampus (Whitehouse et al., 
1982). Acetylcholinesterase inhibitors 
(AChEI) e.g., donepezil are thus being used 
for the symptomatic treatment of Alzhei-
mer's disease to enhance cholinergic neuro-
transmission indirectly, by inhibiting the 
enzyme which hydrolyses acetylcholine 
(Musiał et al., 2007). 
The aims of the present study were 
therefore to: (1) study the behavioral altera-
tions associated with long-term administra-
tion of cannabis preparations on spatial 
learning and memory; (2) investigate the 
effect of memory enhancing drugs pirace-
tam, vinpocetine, Ginkgo biloba and the 
acetylcholine esterase inhibitor donepezil 
for their possible modulation of the canna-
bis-induced memory alterations; (3) detect 
alterations in the level of the brain neuro-
transmitters dopamine, serotonin (5-HT) 
and noradrenaline; (4) assess the effect of 
cannabis administration on oxidative stress 
markers in brain since oxidative stress has 
been implicated in memory impairment 
(Clausen et al., 2010). In addition, the effect 
of cannabis on liver oxidative stress and 
liver enzymes under the different experi-
mental conditions was studied. A total ex-
tract from Cannabis sativa was used based 
on the fact that the effect of the whole plant 
which is abused by humans differs from 
that of THC in view of its content of other 
cannabinoids, terpenoids and flavonoids 
(Russo and McPartland, 2003).  
 
MATERIALS AND METHODS 
Animals 
Swiss male albino mice 20-22 g of body 
weight were used. Standard laboratory food 
and water were provided ad libitum. Ani-
mal procedures were performed in accord-
ance with the Ethics Committee of the Na-
tional Research Centre and followed the 
recommendations of the National Institutes 
of Health Guide for Care and Use of Labor-
atory Animals (Publication No. 85-23, re-
vised 1985). Equal groups of 6 mice each 
were used in all experiments. 
 
Drugs  
Vinpocetine (Vinporal, Amrya. Pharm. 
Ind., Cairo, ARE), piracetam (Nootropil, 
Chemical Industries Development; CID, 
Cairo, ARE), Ginkgo biloba (EMA Pharm. 
Co., Cairo, A.R.E) and scopolamine (Sig-
ma, USA) were used. All drugs were dis-
solved in isotonic (0.9 % NaCl) saline solu-
tion immediately before use. The doses of 
drugs used in the study were based upon the 
human dose after conversion to that of mice 
according to Paget and Barnes conversion 
tables (1964). Cannabis sativa L. plant was 
supplied by the Ministry of Justice - Egypt. 
 
Preparation of cannabis extract 
Cannabis sativa extract was prepared 
from the dried flowering tops and leaves of 
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the plant. The method of extraction fol-
lowed that described by Turner and Mahl-
berg (1984) with modification as described 
elsewhere (Abdel-Salam et al., 2012). Tet-
rahydrocannabinol (THC) content was 
quantified using GC mass. The 9-THC 
content of the extract was 10 %. The extract 
was injected intraperitoneally at doses of 5, 
10 or 20 mg/kg (expressed as 9-THC). The 
injection volume was 0.2 ml/mice.  
 
Cognitive testing 
The maze consisted of a glass tank, nar-
rowed to 20 cm wide, 40 cm in height, 
70 cm in length, filled to a depth of 21 cm 
with water maintained at 25 °C. The escape 
glass platform was hidden from sight, sub-
merged 1 cm below the surface of the water 
at the end of the tank (Dunnett et al., 2003). 
The effect of cannabis extract was studied 
in normal mice and in mice treated with 
scopolamine (1 mg/kg, i.p.) to induce cog-
nitive impairment (Smith et al., 2002). Mice 
were treated with scopolamine alone or in 
combination with cannabis (20 mg/kg, s.c.) 
(n = 6/group) 30 min prior to testing. In ad-
dition, the effect of cannabis extract 
(20 mg/kg, s.c.) was studied in mice treated 
with memory enhancing drugs piracetam 
(150 mg/kg, s.c.), vinpocetine (1.5 mg/kg, 
s.c.), Ginkgo biloba (25 mg/kg, s.c.) and the 
acetylcholinesterase inhibitor donepezil 
(1 mg/kg, s.c.) for their possible modulation 
of the Cannabis sativa-induced memory 
alterations. Treatments were given once 
daily for 30 days. Each test consisted of 
three trials involving placing the mouse in 
the water maze with the platform hidden 
until it finds the platform, leaving it on the 
platform for 15 s, and then retesting the 
mouse from the same start position 3 min 
later (trial 1; reference memory or acquisi-
tion trial; trials 2 & 3; working memory or 
retrieval trials). This was done 3 times a 
week for 4 weeks. At the end of each trial, 
the mouse was towel dried, returned to its 
home cage (where a heat lamp was availa-
ble). The latency to find the platform (s) is 
assessed with a stopwatch.  
 
Biochemical studies  
At the end of the study, mice were eu-
thanized by decapitation, brains and livers 
were then removed, washed with ice-cold 
saline solution (0.9 % NaCl), weighed and 
stored at -80 ºC for the biochemical anal-
yses. The tissues were homogenized with 
0.1 M phosphate buffer saline at pH 7.4, to 
give a final concentration of 10 % w/v for 
the biochemical assays. For the determina-
tion of monoamine neurotransmitters, fro-
zen brain samples were homogenized in 
cold 0.1 N-perchloric acid.  
 
Determination of lipid peroxidation 
Lipid peroxidation was assayed in brain 
and liver homogenates by measuring the 
level of malondialdehyde (MDA). 
Malondialdehyde was determined by meas-
uring thiobarbituric reactive species using 
the method of Ruiz-Larrea et al. (1994) in 
which the thiobarbituric acid reactive sub-
stances react with thiobarbituric acid to 
produce a red colored complex having peak 
absorbance at 532 nm. 
 
Determination of reduced glutathione  
Reduced glutathione (GSH) was deter-
mined by Ellman's method (1959). The pro-
cedure is based on the reduction of 
Ellman´s reagent by –SH groups of GSH to 
form 2-nitro-s-mercaptobenzoic acid, the 
nitromercaptobenzoic acid anion has an in-
tense yellow color which can be determined 
spectrophotometrically.  
 
Determination of nitric oxide  
Nitric oxide measured as nitrite was de-
termined by using Griess reagent, according 
to the method of Moshage et al. (1995), 
where nitrite, stable end product of nitric 
oxide radical, is mostly used as indicator 
for the production of nitric oxide.  
 
Determination of liver enzymes 
Aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) activities 
in liver were measured according to Reit-
man-Frankel colorimetric transaminase 
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procedure (Crowley, 1967) using commer-
cially available kits (BioMérieux, France). 
 
Determination of brain glucose 
Brain tissue glucose content was deter-
mined according to the method of Trinder 
(1969). Glucose in the presence of glucose 
oxidase is converted to peroxide and glu-
conic acid. The produced hydrogen perox-
ide reacts with phenol and 4-amino-
antipyrine in the presence of peroxidase to 
yield a colored quinonemine, which is 
measured spectrophotometrically. 
 
Determination of brain monoamines 
Determination of brain serotonin, nor-
adrenaline and dopamine was carried out 
using high performance liquid chromatog-
raphy (HPLC) system, Agilent technologies 
1100 series, equipped with a quaternary 
pump (Quat pump, G131A model). Separa-
tion was achieved on ODS reversed phase 
column (C18, 25 x 0.46 cm i.d. 5 µm). The 
mobile phase consisted of potassium phos-
phate buffer/methanol 97/3 (v/v) and was 
delivered at a flow rate of 1 ml/min. UV 
detection was performed at 270 nm and the 
injection volume was 20 µl. The concentra-
tion of both catecholamines and serotonin 
were determined by external standard 
method using peak areas. Serial dilutions of 
standards were injected and their peak areas 
were determined. A linear standard curve 
was constructed by plotting peak areas ver-
sus the corresponding concentrations. The 
concentration in samples was obtained from 
the curve.  
 
Statistical analysis 
Data are expressed as mean ± SEM. The 
data were analyzed by one way ANOVA 
and by repeated measures ANOVA, fol-
lowed by Duncan’s multiple range test, us-
ing SPSS software (SAS Institute Inc., 
Cary, NC). A probability value of less than 
0.05 was considered statistically significant.  
 
RESULTS 
Behavioral testing 
Spatial memory 
Cannabis substantially impaired water 
maze performance. The time taken to find 
the escape platform (latency) was signifi-
cantly delayed by cannabis in a dose-
dependent manner, compared with the sa-
line-treated control group (Figure 1). The 
average mean latency and standard error of 
the mean over 4 weeks for the saline, can-
nabis 5 mg/kg, cannabis 10 mg/kg and can-
nabis 20 mg/kg was 3.19 ± 0.07, 4.78 ± 
0.23, 5.73 ± 0.42 and 7.62 ± 0.52 sec, re-
spectively. There was a significant main 
drug effect (F = 36.63, p = 0.001), a signifi-
cant main effect of days (F = 8.82, p = 
0.001) but no significant main effect for 
trials (F = 1.62, p = 0.207). There was a 
significant drug x days interaction (F = 
1.76, p = 0.006) but no significant drug x 
trial (F = 0.33, p = 0.92) or trial x days in-
teraction (F = 1.25, p = 0.20). 
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Figure 1: Effect of cannabis extract on the la-
tency to find hidden platform in the MWM test. 
Cannabis was administered daily via subcuta-
neous route for one month and observations 
were done three times weekly. Asterisks indi-
cate significant change from the saline control 
group. 
 
Donepezil, piracetam, vinpocetine or 
Ginkgo biloba co-administered with canna-
bis (20 mg/kg) resulted in significantly 
shorter latencies compared with the canna-
bis (20 mg/kg) only-treated group, which 
indicated improved learning and memory 
(Figure 2). The average mean latency and 
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standard error of the mean over 4 weeks for 
the cannabis 20 mg/kg plus donepezil, pi-
racetam, vinpocetine or Ginkgo biloba was 
4.87 ± 0.21, 4.42 ± 0.19, 5.18 ± 0.28 and 
4.65 ± 0.23 sec, respectively compared to 
7.62 ± 0.52 sec for the cannabis 20 mg/kg 
group (Figure 3). Compared with the can-
nabis only group, the escape latency de-
creased by 36.1 %, 42 %, 32 % and 39 % 
by donepezil, piracetam, vinpocetine or 
Ginkgo biloba, respectively. Piracetam re-
sulted in significantly shorter latency com-
pared with vinpocetine by 14.7 %. There 
was a significant main drug effect (F = 
14.45, p = 0.001), a significant main effect 
of days (F = 5.27, p = 0.001), no significant 
main effect of trials (F = 3.42, p = 0.038). 
There was a significant drug x days interac-
tion (F = 3.19, p = 0.001) but no significant 
drug x trial (F = 0.38, p = 0.93) or trial x 
days interaction (F = 1.4, p = 0.11).  
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Figure 2: Effect of cannabis extract combined 
with donepezil, piracetam, vinpocetine or 
Ginkgo biloba on the latency to find hidden 
platform in the MWM test. Cannabis and test 
drugs were administered daily via subcutane-
ous route for one month and observations were 
done three times weekly. Asterisks indicate sig-
nificant change from the cannabis only treated 
group. 
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Figure 3: The average mean latency to locate a 
submerged platform in the MWM test over four 
weeks. Mice received daily injections of saline 
or cannabis extract (5, 10 or 20 mg/kg) alone or 
combined with donepezil, piracetam, vinpoce-
tine or Ginkgo biloba and were tested three 
times weekly. Asterisks indicate significant 
change from the saline control group and be-
tween different groups as shown in the figure. 
The plus sign indicates significant change from 
the cannabis 20 mg/kg group. The # sign indi-
cates significant change from the cannabis 
10 mg/kg group. Other statistical comparisons 
between different treated groups are also 
shown and are indicated by asterisks. 
 
In the first trial, the time taken to find 
the escape platform was significantly de-
layed by Cannabis sativa (Figure 7A). 
There was a significant main effect of drug 
(F = 18.61, p = 0.001), a significant main 
effect of days (F = 2.18, p = 0.017) but no 
significant drug x days interaction (F = 
0.86, p = 0.69). Mice treated with cannabis 
20 mg/kg in combination with donepezil, 
piracetam, vinpocetine or Ginkgo biloba 
exhibited significantly shorter escape laten-
cies compared with cannabis (20 mg/kg) 
only-treated group, suggesting improve-
ment of the cognitive impairing effects of 
cannabis by these drugs. There was a sig-
nificant main effect of drug (F = 5.0, p = 
0.004), a significant main effect of days  (F 
= 2.09, p = 0.021) but no significant drug x 
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days interaction (F = 0.97, p = 0.54). The 
average mean for the saline, cannabis 
5 mg/kg, cannabis 10 mg/kg and cannabis 
20 mg/kg was 3.33 ± 0.14, 5.24 ± 0.47, 6.02 
± 0.45, 8.27 ± 0.44 sec, respectively. The 
average mean latency and standard error of 
the mean over 4 weeks for the cannabis 
20 mg/kg plus donepezil, piracetam, 
vinpocetine or Ginkgo biloba was 5.64 ± 
0.46, 5.11 ± 0.47, 5.54 ± 0.42 and 5.08 ± 
0.43 sec, respectively (Figure 4A). Com-
pared with the cannabis only group, the es-
cape latency decreased by 31.8 %, 38.2 %, 
33 % and 38.6 % by donepezil, piracetam, 
vinpocetine or Ginkgo biloba, respectively. 
No significant differences were observed 
between the different drugs in trial 1.  
In the second trial, mice that received 
10 or 20 mg/kg of cannabis were also de-
layed compared with the saline-treated 
group in escaping from the water maze 
(Figure 4B). There was a significant main 
effect of drug (F = 14.89, p = 0.001), a sig-
nificant main effect of days  (F = 3.86, P= 
0.001) but no significant drug x days inter-
action (F = 1.13, p = 0.29). Donepezil, pi-
racetam, vinpocetine or Ginkgo biloba co-
administered with cannabis (20 mg/kg) im-
proved performance resulting in significant-
ly shorter latencies to find the hidden plat-
form than the cannabis (20 mg/kg) only-
treated group (Figure 4B). There was a sig-
nificant main effect of drug (F = 4.73, P = 
0.006), a significant main effect of days  (F 
= 2.76, p = 0.002) and a significant drug x 
days interaction (F = 1.95, p = 0.001). The 
average mean for the saline, cannabis 
5 mg/kg, cannabis 10 mg/kg and cannabis 
20 mg/kg was 3.15 ± 0.11, 4.38 ± 0.36, 5.33 
± 0.43 and 7.57 ± 0.50 sec, respectively. 
The average mean latency and standard er-
ror of the mean over 4 weeks for the canna-
bis 20 mg/kg plus donepezil, piracetam, 
vinpocetine or Ginkgo biloba was 4.39 ± 
0.28, 4.22 ± 0.29, 5.09 ± 0.32 and 4.98 ± 
0.21 sec, respectively. Compared with the 
cannabis only group, the escape latency de-
creased by 42 %, 44.2 %, 32.8 % and 
34.2 % by donepezil, piracetam, vinpoce-
tine or Ginkgo biloba, respectively. Pirace-
tam resulted in significantly shorter latency 
compared with vinpocetine by 17.1 %. 
In the third trial, mice that received 
cannabis took significantly more time to 
find the escape platform compared with the 
saline-treated group (Figure 4C). There was 
a significant main effect of drug (F = 7.36, 
p = 0.002), a significant main effect of days  
(F = 5.12, p = 0.001) but no significant drug 
x days interaction (F = 0.96, P = 0.53). 
Donepezil, piracetam, vinpocetine or Gink-
go biloba co-administered with cannabis 
(20 mg/kg) resulted in significantly shorter 
latencies compared with cannabis (20 mg/ 
kg) only-treated group (Figure 4C). There 
was a significant main effect of drug (F = 
5.60, P = 0.002), a significant main effect 
of days  (F = 3.65, p = 0.0001) and a signif-
icant drug x days interaction (F = 2.0, p = 
0.001). The average mean for the saline, 
cannabis 5 mg/ kg, cannabis 10 mg/kg and 
cannabis 20 mg/ kg was 3.06 ± 0.1, 4.71 ± 
0.36, 5.85 ± 0.41 and 7.02 ± 0.60 sec, re-
spectively. The average mean latency and 
standard error of the mean over 4 weeks for 
the cannabis 20 mg/ kg plus donepezil, pi-
racetam, vinpocetine or Ginkgo biloba was 
4.95 ± 0.31, 3.94 ± 0.20, 4.91 ± 0.26 and 
3.89 ± 0.19 sec, respectively. Compared 
with the cannabis only group, the escape 
latency decreased by 29.4 %, 43.9 %, 
30.1 % and 44.6 % by donepezil, piracetam, 
vinpocetine or ginkgo biloba, respectively. 
Piracetam or Ginkgo biloba resulted in sig-
nificantly shorter latency compared with 
vinpocetine by 19.7 % and 20.1 % and 
compared with donepezil by 20.4 %, 
21.4 %, respectively. 
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Scopolamine (1 mg/kg, i.p.) substantial-
ly impaired cognitive performance leading 
to higher latencies to locate the submerged 
platform compared with the saline-treated 
group. Mice treated with scopolamine and 
cannabis (10 or 20 mg/kg, sc) needed sig-
nificantly more time to locate the hidden 
platform than the scopolamine only-treated 
group, suggesting enhancement of the cog-
nitive impairing effects of scopolamine by 
cannabis (Figures 5, 6) (2-way repeated 
measures ANOVA; drug effect: F = 2.19, p 
= 0.09). There was no significant effect of 
trials (F = 1.71, p = 0.19) and no significant 
main effect of days (F = 0.89, p = 0.55). 
There was a significant drug x days interac-
tion (F = 1.69, P = 0.01) but no significant 
drug x trial (F = 0.37, p = 0.89) or trial x 
days interaction (F = 0.83, p = 0.69). The 
average mean latency and standard error of 
the mean over 4 weeks for the saline, sco-
polamine 1 mg/kg and the scopolamine plus 
cannabis at 5, 10 or 20 mg/kg was 3.13 ± 
0.06, 6.92 ± 0.35, 6.32 ± 0.23, 8.07 ± 0.47 
Figure 4A-C: The average mean latency (in 
seconds) ± SEM of first (A); second (B) and 
third (C) trial to locate a submerged platform 
in the MWM test over four weeks. Mice re-
ceived daily injections of saline or cannabis 
extract (5, 10 or 20 mg/kg) alone or combined 
with donepezil, piracetam, vinpocetine or 
Ginkgo biloba and were tested three times 
weekly. Asterisks indicate significant change 
from the saline control group. The plus sign 
indicates significant change from the canna-
bis 20 mg/ kg group. The # sign indicates 
significant change from the cannabis 10 mg/ 
kg group. 
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and 9.04 ± 0.63 sec, respectively. The time 
taken to find the escape platform was sig-
nificantly delayed by scopolamine alone or 
in combination with cannabis compared 
with the saline treated group in the first, 
second and third trial (2-way repeated 
measure ANOVA: drug effect: trial 1: F = 
1.11, p = 0.37; trial 2: F = 0.5, p = 0.69; tri-
al 3: F = 1.22, p = 0.33). There was no sig-
nificant main effect of days on the escape 
latency and no significant drug x days in-
teraction in all trials (data not shown). In 
the second trial, mice treated with scopola-
mine + 20 mg/kg cannabis showed signifi-
cantly higher latencies to find the hidden 
platform compared with scopolamine + 
5 mg/kg cannabis-treated group. In the third 
trial mice that received scopolamine + 
20 mg/kg cannabis showed significantly 
higher latencies to find the submerged plat-
form compared with other groups (Figure 
7A-C).  
Sc
op
ola
mi
ne
 1m
g/k
g
+ C
an
na
bis
 5 
mg
/kg
+ C
an
na
bis
 10
 m
g/k
g
+ C
an
na
bis
 20
 m
g/k
g 
0
2
4
6
8
10
12
* *
*
*
Es
ca
pe
 la
te
nc
y 
(s
ec
)
 
Figure 5: Effect of cannabis extract on the la-
tency to find hidden platform in the MWM test in 
mice treated with scopolamine (1 mg/kg, s.c.). 
The columns represent the first, second and 
third trail, respectively for each treatment group. 
Asterisks indicate significant change from trial 
1. 
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Figure 6: The average mean latency to locate a 
submerged platform in the MWM test over four 
weeks. Mice received daily injections of scopol-
amine (1 mg/kg, s.c.) or cannabis extract (5, 10 
or 20 mg/kg) and were tested three times week-
ly. Asterisks indicate significant change from 
the saline control group. The plus sign indicates 
significant change from the scopolamine + can-
nabis 20 mg/kg group.  
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EXCLI Journal 2013;12:193-214 – ISSN 1611-2156 
Received: February 13, 2013, accepted: February 27, 2013, published: March 12, 2013 
 
202 
Sa
lin
e
Sc
op
ola
mi
ne
 1 
mg
/kg
+ C
an
na
bis
 5 
mg
/kg
+ C
an
na
bis
 10
 m
g/k
g
+ C
an
na
bis
 20
 m
g/k
g
0.0
2.5
5.0
7.5
10.0
12.5
* *
*
*
B
Es
ca
pe
 la
te
nc
y 
(s
ec
)
 
Sa
lin
e
Sc
op
ola
mi
ne
 1 
mg
/kg
+ C
an
na
bis
 5 
mg
/kg
+ C
an
na
bis
 10
 m
g/k
g
+ C
an
na
bis
 20
 m
g/k
g
0.0
2.5
5.0
7.5
10.0
*
*
*
*
C +
Es
ca
pe
 la
te
nc
y 
(s
ec
)
Figure 7 A-C: The average mean latency of 
first (A); second (B) and third (C) trial to locate a 
submerged platform in the MWM test over four 
weeks. Mice received daily injections of saline, 
scopolamine (1 mg/kg, s.c.) or scopolamine 
plus cannabis (5, 10 or 20 mg/kg) and were 
tested three times weekly. Asterisks indicate 
significant change from the saline control group. 
The plus sign indicates significant change from 
the scopolamine only or scopolamine + canna-
bis 5 mg/kg group.  
 
BIOCHEMICAL RESULTS 
Effect of cannabis on markers of oxidative 
stress and glucose in brain 
Cannabis alone 
The administration of cannabis altered 
the redox status in brain with the effect be-
ing significant with the high dose of the ex-
tract which resulted in 20.2 % decrease in 
MDA compared with the saline-treated 
group (26.71 ± 0.96 vs. 33.47 ± 1.34 
nmol/g). Brain GSH showed significant in-
crease by 24.2 % after cannabis at 20 mg/kg 
(4.1 ± 0.20 vs. 3.3 ± 0.13 µmol/g, p<0.05). 
Meanwhile, the administration of cannabis 
at 20 mg/kg resulted in a significant de-
crease in brain nitrite by 32.8 % (34.48 ± 
3.3 vs. 51.3 ± 3.1 µmol/g, p<0.05) and in 
brain glucose by 30.2 % (35.1 ± 1.9 vs. 50.3 
± 3.5 µg/g, p<0.05) (Figure 8 A-D).  
Cannabis in combination with memory en-
hancing drugs 
The level of MDA in brain increased 
significantly by 23.8 % after the administra-
tion of piracetam (33.08 ± 0.76 vs. 26.71 ± 
0.96 nmol/g, p<0.05). Meanwhile, brain 
nitrite and glucose which decreased by can-
nabis were restored to near normal values 
by piracetam, registering 29.1% (44.5 ± 2.9 
vs. 34.48 ± 3.3 µmol/g, p<0.05) and 36.2 % 
(47.8 ± 2.0 vs. 35.1 ± 1.9 µg/g, p<0.05) in-
crements compared with the 20 mg/kg can-
nabis only-treated group. On the other 
hand, the administration of donepezil, 
vinpocetine or Ginkgo biloba resulted in 
significant increase in brain GSH by 
36.6 %, 41.5 % and 117.1 %, respectively 
(Figure 8A-D)  
Cannabis in combination with scopolamine  
The administration of scopolamine at 
the dose of 1 mg/kg did not change brain 
MDA or glucose level. However, the level 
of nitric oxide increased by 15.7 % and 
GSH significantly decreased by 27.3 % by 
scopolamine vs. saline control value (2.4 ± 
0.12 vs. 3.3 ± 0.13 µmol/g, p<0.05). In sco-
polamine-treated mice, the administration 
of cannabis extract decreased MDA in a 
dose-dependent manner. A significant de-
crease in MDA level by 26.2 % and 31.7 % 
was observed after the administration of 
cannabis extract 10 or 20 mg/kg, respec-
tively (27.87 ± 1.04 and 25.76 ± 0.98 vs. 
37.74 ± 1.23 nmol/g, p<0.05). The level of 
glutathione was significantly increased by 
29.2 % (p<0.05) and 62.5 % (p<0.05) after 
the administration of cannabis extract at the 
doses of 10 and 20 mg/kg, respectively, 
compared with the scopolamine only-
EXCLI Journal 2013;12:193-214 – ISSN 1611-2156 
Received: February 13, 2013, accepted: February 27, 2013, published: March 12, 2013 
 
203 
treated group (3.1 ± 0.0.16 and 3.9 ± 0.26 
vs. 2.4 ± 0.12 µmol/g, p<0.05). The level of 
nitrite significantly decreased by 26.3 % 
after cannabis at 20 mg/kg, while glucose 
level significantly decreased by 16.7 % and 
30.6 % after cannabis at 10 and 20 mg/kg, 
respectively vs. scopolamine only-treated 
group (Figure 8 A-D).  
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Figure 8 A-D: Effect of cannabis extract alone 
or in combination with piracetam, vinpocetine, 
Ginkgo biloba, donepezil or scopolamine on 
brain malondialdehyde (MDA), reduced gluta-
thione (GSH), nitric oxide and glucose in mice. 
*: p< 0.05 vs corresponding saline control val-
ue. +: p< 0.05 vs. cannabis (20 mg/kg) only-
treated group. #: p< 0.05 vs scopolamine only-
treated group 
 
Effect of cannabis on brain monoamines 
In saline-treated mice, a dose-dependent 
elevation of serotonin, noradrenaline and 
dopamine was observed after treatment 
with cannabis extract alone at tested doses 
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of 5, 10 and 20 mg/kg. In mice given 
20 mg/kg of cannabis, the increment in ser-
otonin was ameliorated by the memory en-
hancing drugs donepezil, piracetam, 
vinpocetine or Ginkgo biloba. Noradrena-
line was restored to its normal value by 
donepezil, vinpocetine or ginkgo biloba, but 
increased by piracetam. The level of dopa-
mine was significantly reduced by pirace-
tam, vinpocetine or Ginkgo biloba, but not 
by donepezil (Table 1). In mice treated with 
scopolamine, a significant increase in sero-
tonin and dopamine by cannabis at 20 mg/ 
kg was observed. 
 
Effect of cannabis on markers of oxidative 
stress in liver 
The effect of cannabis on oxidative 
markers in the liver was also examined. The 
administration of cannabis extract (5, 10 or 
20 mg/kg) did not alter the level of MDA, 
GSH or nitrite in hepatic tissue. In mice 
given 20 mg/kg cannabis extract, the ad-
ministration of Ginkgo biloba significantly 
decreased nitrite level (85.0 ± 5.1 vs. 102.4 
± 6.1 µmol/g, p<0.05). Meanwhile, GSH 
showed further increase by 17.2% in mice 
treated with Ginkgo biloba (12.9 ± 1.1 vs. 
11.01 ± 3.1 µmol/g, p<0.05). Liver alanine 
aminotransferase and aspartate aminotrans-
ferase were not altered in mice given 20 
mg/kg cannabis alone or with memory en-
hancing drugs (Table 2). 
 
 
Table 1: Effect of cannabis extract, scopolamine or cannabis + scopolamine on brain monoamines 
 Serotonin 
(µg/g tissue) 
Dopamine 
(µg/g tissue) 
Noradrenaline 
(µg/g tissue) 
Saline 2.83  0.20 2.94  0.05 1.95  0.15 
+ Cannabis 5 mg/kg 5.23  0.26* 4.65  0.51* 2.10  0.08 
+ Cannabis 10 mg/kg 5.19  0.23* 7.88  0.11* 2.22  0.12* 
+ Cannabis 20 mg/kg 5.56  0.47* 11.4  0.65* 2.55  0.11* 
Cannabis 20 mg/kg + donepezil  
1 mg/kg 
1.45  0.05*+ 14.62  1.61*+ 1.58  0.08+ 
Cannabis 20 mg/kg + piracetam 
150 mg/kg 
1.95  0.07*+ 4.65  0.51*+ 3.85  0.23*+ 
Cannabis 20 mg/kg + vinpocetin 
3 mg/kg 
1.06  0.09*+ 5.71  0.33*+ 1.95  0.17+ 
Cannabis 20 mg/kg + Ginkgo 
biloba 25 mg/kg 
2.01  0.18*+ 4.64  0.52*+ 3.44  0.43*+ 
Scopolamine 1 mg/kg 1.84  0.21* 5.68  0.41* 1.84  0.21 
+ Cannabis 5 mg/kg 1.91  0.12 5.43  0.34* 1.77  0.12 
+ Cannabis 10 mg/kg 1.96  0.13 5.49  0.24* 1.91  0.15 
+ Cannabis 20 mg/kg 2.82  0.22+ 7.92  0.63*+ 1.96  0.13 
Results are mean ± S.E. Six mice were used per each group. Data were analyzed by one way ANOVA and 
means of different groups were compared by Duncan’s multiple range test. P<0.05 was considered statistically 
significant. *: P<0.05 vs. saline control group. +: P<0.05 vs. the scopolamine control group 
 
Table 2: Effect of cannabis extract given with donepezil, piracetam, vinpocetine or Ginkgo biloba on 
liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
 Saline Cannabis 20 mg/kg 
+ donepezil  
1 mg/kg 
Cannabis 20 mg/kg + 
piracetam 150 mg/kg 
Cannabis  
20 mg/kg + 
vinpocetine  
3 mg/kg 
Cannabis  
20 mg/kg + 
Ginkgo biloba  
25 mg/kg 
AST 66.8 ± 4.2 67.9 ±1.9 66.1 ± 2.1 65.3 ± 2.0 55.5 ± 5.3 
ALT 31.1 ± 1.9 35.2 ± 2.1 32.5 ± 1.4 34.8 ± 2.0 30.9 ± 1.1 
Results are mean ± S.E. Six mice were used per each group. Data were analyzed by one way ANOVA and 
means of different groups were compared by Duncan’s multiple range test. 
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The administration of scopolamine did 
not alter liver malondialdehyde or nitric ox-
ide level. However, the level of GSH was 
significantly decreased by 31.7 % (p<0.05) 
by scopolamine vs. saline control value 
(7.65 ± 1.3 vs. 11.2 ± 2.4 µmol/g, p<0.05). 
In scopolamine-treated mice, the admin-
istration of cannabis at 5, 10 or 20 mg/kg 
increased liver GSH in a dose-dependent 
manner (33.3 %, 38.6 % and 50.3 % in-
crease vs. scopolamine only-treated group) 
(Figure 9 A-C).  
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Figure 9 A-C: Effects of cannabis extract 
alone, cannabis + memory enhancing drugs or 
cannabis + scopolamine on liver malondialde-
hyde (MDA), reduced glutathione (GSH) and 
nitric oxide in mice. *: p< 0.05 vs corresponding 
vehicle control value. +: p< 0.05 vs. cannabis 
(20 mg/kg) only-treated group 
 
 
DISCUSSION 
In the present study the effect of canna-
bis extract with known Δ9-THC content on 
working memory and on oxidative stress in 
brain and liver of mice was investigated. 
The repeated daily administration of the 
extract at doses corresponding to 5, 10 and 
20 mg Δ9-THC/kg was associated with im-
paired learning and memory when tested in 
the water maze test. Mice given cannabis 
spent more time to locate the hidden plat-
form than their untreated counterparts. The 
effect was most evident with the initial ad-
ministration of the extract and maintained 
throughout the study. There was a clear 
dose-related response during the three trials 
of the test. Scopolamine, an anticholinergic 
drug, impaired memory performance in the 
water maze test which is in accordance with 
other studies (Smith et al., 2002). Mice 
treated with scopolamine and cannabis 
needed significantly more time to locate the 
hidden platform than the scopolamine only-
treated group, suggesting exacerbation of 
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the cognitive impairing effects of scopola-
mine by cannabis. Studies have shown that 
cannabis preparations or their primary psy-
choactive constituent Δ9-THC affect 
memory processing in humans and in ex-
perimental animals. Prose recall and source 
memory were poorer in daily users with 
high THC levels in hair (Morgan et al., 
2011). In healthy volunteers, Δ9-THC (2.5, 
and 5 mg) given intravenously disrupted 
immediate and delayed word recall, im-
paired performance tests of distractibility, 
verbal fluency and working memory 
(D'Souza et al., 2004). Similarly, orally 
given Δ9-THC led to acute impairment of 
attentional functioning and working 
memory (Roser et al., 2008). Impaired 
memory performance has been reported in 
mice after the oral administration of hashish 
extract in dosages corresponding to 1, 5, 
and 10 mg Δ9-THC/kg (Frischknecht et al., 
1985) and after inhalation of marijuana 
smoke (Niyuhire et al., 2007) and in rats 
following intraperitoneal injection of Δ9-
THC-rich extracts (2 or 5 mg/kg) (Fadda et 
al., 2004). Cannabidiol, another constituent 
of the plant Cannabis sativa, that does not 
possess psychoactive properties, appeared 
to antagonize the memory impairing effect 
of Δ9-THC in the same extract (Fadda et al., 
2004), though not the working memory def-
icits induced by scopolamine and dizocil-
pine (Fadda et al., 2006). The cannabis in-
duced memory alterations are likely to be 
mediated by 9-THC-inducecd activation of 
cannabinoid CB1 receptor in brain. Delta 
(9)-THC-rich extracts impaired memory 
performance in rats (Fadda et al., 2004), 
while 9-THC-induced spatial memory im-
pairment was reversed by cannabinoid 
CB(1) receptor antagonist, suggesting that 
the effect of 9-THC is mediated through 
cannabinoid CB(1) receptors (Egashira et 
al., 2012). Studies also suggested the in-
volvement of prefrontal dopamine receptors 
(Rodrigues et al., 2011) as well as μ- and κ-
opioid receptors (Egashira et al., 2012) in 
9-THC-induced disruption of spatial work-
ing memory. Cannabis effect on learning 
and memory processes probably involves 
depolarization-induced suppression of ex-
citatory mechanism in the CA1 area of hip-
pocampus (Ebrahimpour et al., 2010). 
Of the important findings in the present 
studies is the effect of cannabis on neuro-
transmitter levels in brain. It is evident that 
the repeated administration of cannabis ex-
tract increased brain levels of serotonin, 
noradrenaline and dopamine. Other studies 
have shown increased dopamine and nora-
drenaline release in rodent brain by THC in 
several regions of the brain, including stria-
tal, nucleus accumbens and prefrontal areas 
(Muntoni et al., 2006; Robledo et al., 2007). 
Moreover, increased release of norepineph-
rine in the rat frontal cortex was observed 
after systemic administration of the synthet-
ic cannabinoid agonist WIN 55,212-2 
(Oropeza et al., 2005). In healthy human 
subjects, THC induced dopamine release in 
the human striatum (Bossong et al., 2009). 
As for 5HT, 9-THC attenuated methylene-
dioxymethamphetamine (MDMA)-induced 
decreases in 5-HT levels and in serotonin 
transporter (SERT) binding in the frontal 
cortex, parietal cortex, and striatum (Shen 
et al., 2011) while stimulating CB-1 de-
creased the effect of citalopram on increas-
ing serotonin levels in the prefrontal cortex 
(Kleijn et al., 2011). In contrast, rats inject-
ed with the synthetic cannabinoid HU210 
exhibited increased 5HT1A receptor densi-
ty and mRNA expression in the CA1 region 
of the hippocampus (Zavitsanou et al., 
2010). These effects of cannabis on brain 
monoamines could account for the cogni-
tive and attention deficits and anxiety reac-
tions seen in cannabis users. Cannabis sati-
va, however, contains many constituents 
including over 70 different cannabinoids 
(Hollister, 1988). Thus cannabis can result 
in different effects from those of 9-THC 
alone. For example, cannabigerol a non-
psychoactive constituent behaved as a po-
tent alpha (2) adrenoceptor agonist and a 
5HT(1A) antagonist (Cascio et al., 2010). 
Meanwhile, cannabidiol, another non-
psychoactive increased extracellular dopa-
mine levels in nucleus accumbens (Murillo-
Rodríguez et al., 2011). While 9-THC acts 
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as a CB1 and CB2 receptor partial agonist, 
9-tetrahydrocannabivarin, behaves either 
as a CB1 antagonist or, at higher doses, as a 
CB1 receptor agonist (Pertwee, 2008). The 
present study has also provided evidence 
that the nootropic drugs piracetam, 
vinpocetine, Ginkgo biloba or donepezil 
were capable of modulating neurotransmit-
ter levels in mice treated with cannabis. 
Serotonin was decreased by all drugs. Nor-
adrenaline was normalized by vinpocetine 
and donepezil though increased by pirace-
tam and Ginkgo biloba. Meanwhile, pirace-
tam, vinpocetine, Ginkgo biloba decreased 
the cannabis-induced increments in dopa-
mine. Studies have shown that most 
nootropics influencing cognitive mecha-
nisms affect neurotransmitters levels in 
brain. Vinpocetine through selective block-
ade of voltage-sensitive presynaptic Na+ 
channels inhibits the transporter-mediated 
release of monoamine neurotransmitters. 
The drug impairs the vesicular storage of 
dopamine as well (Trejo et al., 2001). 
Ginkgo biloba has been shown to increase 
central dopamine, noradrenaline (Yoshitake 
et al., 2010) and 5-HT (Blecharz-Klin et al., 
2009) levels. Piracetam increases dopamine 
in cortex and striatum (Wustmann et al., 
1990; Stancheva and Alova, 1994). In one 
study, piracetam abolished the amnestic ef-
fect of 6-hydroxydopamine and restored to 
control values the noradrenaline level in the 
frontal cortex and hippocampus (Gouliaev 
and Senning, 1994). Donepezil administra-
tion was associated with a significantly in-
creased release of dopamine (Liang and 
Tang, 2006), noradrenaline (Shearman et 
al., 2006) in cortex or hippocampus, but 
decreased extracellular serotonin levels 
(Shearman et al., 2006).  
The effect of cannabis on brain oxida-
tive stress, an imbalance between free radi-
cals generation and antioxidant defense 
mechanisms is important in view of the ev-
idence linking cellular damage arising from 
increased oxidative stress to neuronal de-
generation and decline in cognitive function 
associated with normal aging or caused by 
different pathological states (Dröge, 2003; 
Zhou et al., 2008; Halliwell, 2006). The 
present study suggests that cannabis extract 
alters the oxidative balance in the brain. 
This however, appears to be in favor of re-
ducing lipid peroxidation. Malondialdehyde 
an index of lipid peroxidation activity (Gut-
teridge, 1995), is decreased and there was 
significant increase of GSH, an important 
antioxidant defense system, especially with 
the highest dose of cannabis examined. Ni-
tric oxide in brain is also decreased by can-
nabis administration. The significance of 
this finding is yet to be determined. Nitric 
oxide is an important signaling molecule 
involved in neurotransmission and in main-
taining vascular tone via its vasodilator 
properties. Nitric oxide can be also detri-
mental to neural tissue if generated in ex-
cess by inflammatory cytokines due to the 
action of inducible nitric oxide synthase 
(Moncada et al., 1991). In mice treated with 
the anticholinergic drug scopolamine so as 
to produce memory deficits, lipid peroxida-
tion, though not significantly increased by 
scopolamine is decreased to normal value 
by the highest dose of cannabis. Reduced 
glutathione which is decreased by scopola-
mine is restored by cannabis administration. 
The extract also lessened the increase in 
brain nitric oxide by scopolamine. Still 
brain glucose decreased after cannabis ad-
ministration under these conditions. These 
findings confirm observations in the saline-
treated mice. These results are intriguing in 
view of the studies reporting neuroprotec-
tive effects for certain cannabinoids under 
experimental substances (Pazos et al., 
2012). These antioxidant properties of the 
cannabis extract can be explained by the 
fact that cannabis extract is not merely 9-
THC, but rather a mixture of over 600 dif-
ferent chemical compounds. Cannabinoids, 
a group of C21 terpenophenolic compounds 
uniquely produced by Cannabis sativa plant 
are considered to be the main biologically 
active constituents of the Cannabis sativa 
plant, of which currently at least 70 are 
known (Brenneisen, 2006). Other canna-
binoids such as cannabidiol (CBD), canna-
binol (CBN) and tetrahydrocannabivarin 
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(THCV) can result in different effects from 
those of 9-THC alone (Pertwee, 2008). 
Some cannabinoids were found to exert 
neuroprotective effects (Pazos et al., 2012). 
The beneficial effects of cannabis extract 
on brain lipid peroxidation can also be as-
cribed to the flavonoids it contains. One 
important finding, however, was the de-
creased brain glucose by cannabis admin-
istration, thereby, impairing cerebral energy 
metabolism. This impairment of brain ener-
getics, can explain the effect of the extract 
on memory function. The oxidative status 
of hepatic tissue was also examined. In con-
trast to the effect of repeated cannabis ex-
tract on oxidative stress in brain, the extract 
did no affect lipid peroxidation or reduced 
glutathione levels in the liver tissue. 
The current study investigated the effect 
of piracetam, vinpocetine, Ginkgo biloba 
extract or donepezil on the memory im-
pairment induced by cannabis extract in the 
water maze test. These drugs are widely 
prescribed to enhance memory function due 
to mild cognitive impairment or Alzhei-
mer's disease (McDaniel et al., 2003). Pi-
racetam, vinpocetine, Ginkgo biloba or 
donepezil co-administered with cannabis 
resulted in significantly shorter latencies 
compared with mice treated with only can-
nabis, which indicated improved learning 
and memory or in other words improve-
ment of the cognitive impairing effects of 
Cannabis sativa by these drugs. This effect 
of cannabis decreased by memory enhanc-
ing drugs with piracetam resulting in the 
most-shorter latency compared with the 
cannabis. Biochemically, cannabis altered 
the oxidative status of the brain with de-
creased MDA, increased GSH, but de-
creased nitric oxide and glucose. In canna-
bis-treated rats, the level of GSH in brain 
showed further increase after vinpocetine 
and donepezil and was markedly elevated 
after Ginkgo biloba. Piracetam restored the 
decrease in glucose and nitric oxide by can-
nabis. Of the memory enhancing drugs used 
in an attempt to counteract the effect of 
cannabis on memory performance, pirace-
tam resulted in the most-shorter latency 
compared with the cannabis. Piracetam re-
sulted in significantly shorter latency com-
pared with vinpocetine over the 4 weeks of 
the study. The effect of piracetam was more 
evident during the second and third trials of 
the test. Moreover, only piracetam signifi-
cantly increased brain glucose compared 
with the cannabis-treated group. The drug 
has been reported to reverse regional de-
pressions in glucose metabolism in the rat 
hippocampus after scopolamine treatment 
(Piercey et al., 1987). When given to pa-
tients with Alzheimer's disease, piracetam 
significantly improved regional glucose 
metabolism in most cortical areas (Heiss et 
al., 1988). Interestingly, GSH is increased 
by donepezil, vinpocetine and Ginkgo bi-
loba. In other studies, vinpocetine and pi-
racetam increased GSH in different brain 
areas (Abdel-Salam et al., 2011). In vitro, 
vinpocetine displayed scavenging activity 
at human therapeutic serum concentration 
(Horvath et al., 2002). Studies indicated an 
antioxidant effect for Ginkgo biloba ex-
tracts. In mice, Ginkgo biloba attenuated 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced neurodegeneration of the 
nigrastriatal pathway, most likely due to an 
inhibitory effect against oxidative stress 
(Rojas et al., 2008). In vitro, Ginkgo biloba 
was able to block A (1–42)-induced cell 
apoptosis, reactive oxygen species accumu-
lation and mitochondrial dysfunction (Shi et 
al., 2009). 
In summary, this study examined can-
nabis induced memory deficits in the Mor-
ris water maze, using mice. Cannabis was 
found to impair performance as measured 
by the time taken to locate a submerged 
platform compared to controls. The positive 
control scopolamine also slowed perfor-
mance and added to the cannabis deficit 
when the two agents were tested together. 
The impaired memory performance is likely 
to involve decreased brain glucose availa-
bility as well as alterations in brain mono-
amine neurotransmitter levels. The cannabis 
induced performance deficit was attenuated 
by the memory enhancing drugs, with pi-
racetam resulting in the most-shorter laten-
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cy compared with the cannabis and restor-
ing the cannabis-induced decrease in brain 
glucose and nitric oxide.  
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